The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

endoluminalsciences.com

Stage

Grant | Alive

Total Raised

$4.5M

Last Raised

$2.5M | 9 yrs ago

About Endoluminal Sciences

Endoluminal Sciences is developing technology for minimally invasive replacement of diseased aortic valves. The technology enables enhancement of the hydrodynamic performance and durability of aortic valve implants/devices. The device prototypes will undergo detailed end-user studies in the hands of a number of interventional cardiologists considered thought-leaders in the field. With the successful completion of these studies the technology will have completed proof-of-concept and will be poised to enter the pre-clinical and clinical phase of commercial development.

Endoluminal Sciences Headquarter Location

4 Cornawallis Street, Suite 145 Eveleigh, NSW

Sydney, New South Wales, 2015,

Australia

+61 2 9209 4213

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Endoluminal Sciences Patents

Endoluminal Sciences has filed 8 patents.

The 3 most popular patent topics include:

  • Cardiac arrhythmia
  • Cardiac surgery
  • Cardiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/21/2012

12/22/2015

Prosthetics, Implants (medicine), Orthopedic surgical procedures, Restorative dentistry, Hematology

Grant

Application Date

5/21/2012

Grant Date

12/22/2015

Title

Related Topics

Prosthetics, Implants (medicine), Orthopedic surgical procedures, Restorative dentistry, Hematology

Status

Grant

Latest Endoluminal Sciences News

Endoluminal Sciences clinical trials planned for heart valve seal technology

Aug 28, 2015

Endoluminal Sciences clinical trials planned for heart valve seal technology Aug28,2015 Joshua Cantem Patients with narrowed aortic valves often cannot even climb a flight of stairs as the flow of blood into their bodies from their hearts is so diminished. And treatment for this life-threatening condition is problematic—with sufferers having only a 50–50 chance of survival beyond two years. If people with this condition are strong enough, they can undergo invasive, major open heart surgery to have a surgical artificial heart valve implanted. But, for those too frail to undergo open heart surgery—that is about a third of sufferers—a transcatheter aortic valve replacement is the only safe treatment option. This minimally invasive surgical procedure allows for the implantation of an artificial heart valve through a keyhole-sized incision in a patient’s groin. However, as many as 50 per cent of the heart valves implanted in this non-invasive way will leak, putting the patient at risk of heart failure and death. New technology being developed and commercialised by the Australian start-up, Endoluminal Sciences Pty Ltd, addresses this leakage problem. “Our Endoseal technology effectively lifts the standard of the valves implanted through minimally invasive surgery to match the level of surgically implanted devices,” says CEO of Endoluminal Sciences , Ashish Mitra. “Our technology is critical in bringing the benefits of minimally invasive surgery to nearly all patients with aortic heart valve disease.” “Our technology has the potential to make open heart surgery a thing of the past.” The technology is designed as a permanent implant, requiring Endoluminal to satisfy strict safety and performance requirements. With pre-clinical trials completed and multiple positive findings on the technology published, clinical trials in Europe in 2016 are the next step in getting this life-saving technology to market. Mitra says, “This technology will allow a greater number of patients to be treated with a minimally invasive technique, which means shorter operations, reduced surgical complications, shorter hospital stays and quicker recovery.” The company has received Australian Government commercialisation support and has entered into a licencing agreement with Swiss company, Symetis , to commercialise the technology. As part of the Government assistance Commercialisation Adviser Topaz Conway has provided strategic mentorship on deal-making and commercialisation and key connections with investors. “This company has succeeded in getting this game-changing technology into the right hands at the right time,” Conway says. This article originally appeared in the Australian Government Dealflow Entrepreneurs Programme Aug-Oct 15. Endoluminal Sciences is a client of ATP Innovations, Australia’s leading business incubator. Share this:

Endoluminal Sciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Endoluminal Sciences Rank

  • Where is Endoluminal Sciences's headquarters?

    Endoluminal Sciences's headquarters is located at 4 Cornawallis Street, Suite 145, Sydney.

  • What is Endoluminal Sciences's latest funding round?

    Endoluminal Sciences's latest funding round is Grant.

  • How much did Endoluminal Sciences raise?

    Endoluminal Sciences raised a total of $4.5M.

  • Who are the investors of Endoluminal Sciences?

    Investors of Endoluminal Sciences include NSW Ministry of Health and GBS Venture Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.